Insider Transactions in Q4 2021 at Kiora Pharmaceuticals Inc (KPRX)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 07
2021
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
91
-0.39%
|
$91
$1.3 P/Share
|
|
Dec 07
2021
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
273
-0.4%
|
$273
$1.3 P/Share
|
|
Nov 18
2021
|
Brian M. Strem President and CEO |
BUY
Open market or private purchase
|
Direct |
17,853
+39.48%
|
$17,853
$1.41 P/Share
|
|
Nov 02
2021
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-0.36%
|
$83
$1.98 P/Share
|
|
Nov 02
2021
|
Brenda Mann VP of Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
62
-0.41%
|
$62
$1.98 P/Share
|
|
Nov 02
2021
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
250
-0.36%
|
$250
$1.98 P/Share
|
|
Oct 21
2021
|
Brian M. Strem President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
9,517
+50.0%
|
-
|
|
Oct 04
2021
|
Stephen From Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
249
-0.36%
|
$498
$2.01 P/Share
|
|
Oct 04
2021
|
Brenda Mann VP of Research & Development |
SELL
Payment of exercise price or tax liability
|
Direct |
62
-0.41%
|
$124
$2.01 P/Share
|
|
Oct 04
2021
|
Sarah Romano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-0.36%
|
$166
$2.01 P/Share
|